Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
Prana Thoracic, a startup focused on earlier detection and intervention for lung cancer, recently won the medical devices track of the MedCity News INVEST Pitch Perfect contest. The company is developing a minimally invasive electrosurgical device to help thoracic surgeons better excise smaller and intermediate-size lung nodules.
Richard Fu details the company's approach to nutrition therapy and strategy for patients using GLP-1s.
In an interview, the deputy director and chief innovation officer of Translational Research Institute for Space Health, headquartered at Baylor College of Medicine, described some of the group's work, adapting known tech for space applications and using space-based insights to improve healthcare at home.
The findings may make it possible to identify a subset of patients who experience poorer outcomes or more serious side effects, especially neurotoxicity.
Data from 11 patients in an MD Anderson study of a cell therapy that uses natural killer (NK) cells from donors instead of patients' own T cells showed a high response rate and low toxicity. A multicenter, international Phase II study is planned.
The Senate voted 72-18 Thursday to confirm Hahn, a radiation oncologist and chief medical executive at The University of Texas MD Anderson Cancer Center.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
HHS announced that it had nominated Dr. Stephen Hahn as the next FDA commissioner. Acting Commissioner Ned Sharpless will return to the National Cancer Institute, while HHS official Brett Giroir will temporarily step in pending Hahn's confirmation.
Dr. Stephen Hahn, a radiation oncologist and MD Anderson's chief medical executive, has reportedly been in the running since September to succeed former FDA Commissioner Scott Gottlieb and current acting commissioner Ned Sharpless.
BioCentury reported that the the nomination of radiation oncologist Dr. Stephen Hahn, who had been under consideration, would follow an FBI background check. Acting Commissioner Ned Sharpless and Brett Giroir, an assistant HHS secretary, had also reportedly been in the running.
Trump is reportedly considering Dr. Stephen Hahn to head the FDA. Others reportedly under consideration include acting Commissioner Ned Sharpless and HHS assistant secretary Brett Giroir.
How Apella leverages technology to increase OR efficiency.
Juliana Garaizar's removal marks the second time in the past 12 months that TMC's leadership is making executive changes at the very top of organizations under its umbrella that are dedicated to startup investing and innovation.
The two organizations are placing particular emphasis on lung and gastrointestinal cancers, as well as drug targets like KRAS mutations.
Oscar, which was initially founded in 2012 to serve the emerging Obamacare insurance exchanges, decided to enter into Medicare Advantage after a $375 million funding round from Alphabet last year.
The Houston-based company is developing a cell therapy for viral infections in patients with compromised immune systems, which it plans to move into Phase III studies within the next 12 months. AlloVir also raised $120 million in a Series B funding round.
Houston-based CorInnova won the medical device track for the Pitch Perfect contest at the MedCity INVEST conference in Chicago.